F 61
Alternative Names: F-61Latest Information Update: 14 Sep 2022
At a glance
- Originator Wuhan Institute of Biological Products
- Class Antibodies; Antivirals
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 02 Aug 2022 Preclinical trials in COVID-2019 infections in China (Intranasal) before August 2022
- 02 Aug 2022 Preclinical trials in COVID-2019 infections in China (IV) before August 2022
- 02 Aug 2022 Wuhan Institute of Biological Products plans a phase I trial for COVID-2019 infection (In volunteers) in China (IV) (NCT05483504)